Trending NewsTrending NewsNASDAQ:GILD Gilead Sciences (GILD) Stock Price, News & Analysis $156.04 -1.15 (-0.73%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$156.99 +0.95 (+0.61%) As of 10/23/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Gilead Sciences Stock (NASDAQ:GILD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gilead Sciences alerts:Sign Up Key Stats Today's Range$155.76▼$157.6550-Day Range$138.92▼$157.3752-Week Range$114.02▼$160.51Volume6.07 million shsAverage Volume5.70 million shsMarket Capitalization$193.48 billionP/E RatioN/ADividend Yield2.10%Price Target$159.81Consensus RatingModerate Buy Company Overview Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19. Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary. The company also researches treatments for areas including liver disease, inflammation and respiratory illnesses. Founded in 1987, Gilead is headquartered in Foster City, California, and serves patients and healthcare providers in markets around the world. The company operates through research, manufacturing and commercial organizations across North America, Europe and other international regions. Daniel O’Day has served as Gilead’s chairman and chief executive officer since 2019.AI Generated. May Contain Errors. Read More Gilead Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreGILD MarketRank™: 3.49799732977 of 5 starsGilead Sciences scored higher than 70% of companies evaluated by MarketBeat, and ranked 222nd out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingModerate Buy Consensus RatingGilead Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 23 buy ratings, 6 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Gilead Sciences is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageGilead Sciences has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Gilead Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Gilead Sciences are expected to grow in the coming year, from ($0.47) to $9.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gilead Sciences is -58.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gilead Sciences is -58.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGilead Sciences has a P/B Ratio of 8.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Gilead Sciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.77% of the float of Gilead Sciences has been sold short.Short Interest Ratio / Days to CoverGilead Sciences has a short interest ratio ("days to cover") of 3.36, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gilead Sciences has recently increased by 19.25%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldGilead Sciences pays a meaningful dividend of 2.09%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGilead Sciences has been increasing its dividend for 10 years.Dividend SustainabilityBased on earnings estimates, Gilead Sciences will have a dividend payout ratio of 33.00% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.Read more about Gilead Sciences' dividend. News and Social Media4.3 / 5News Sentiment0.82 News SentimentGilead Sciences has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 47 news articles for Gilead Sciences this week, compared to 12 articles on an average week.Search Interest39 people have searched for GILD on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows25 people have added Gilead Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 257% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Gilead Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,877,860.00 in company stock.Percentage Held by Insiders0.30% of the stock of Gilead Sciences is held by insiders.Percentage Held by Institutions83.67% of the stock of Gilead Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gilead Sciences' insider trading history. Receive GILD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GILD Stock News HeadlinesGilead Sciences (GILD) Could Be 22% Overvalued Following Its Liver Meeting UpdateOctober 24 at 4:40 AM | finance.yahoo.comThe Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement SchemeOctober 23 at 5:48 PM | finance.yahoo.com“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 yearsDr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehman Brothers, is warning of a developing financial crisis. The New York Times has credited him as among the first to see the dangers ahead, and Forbes dubbed him Mr. Independence. He says this emerging situation could trigger a chain reaction across banks and markets. Watch his free video breakdown and see the five steps he outlines for investors.October 24 at 1:00 AM | Weiss Ratings (Ad)Gilead’s Weekly HIV Pill Study Adds Long-Acting Firepower to GILD’s PipelineOctober 23 at 12:52 PM | tipranks.comGilead Sciences to Pay $45 Million in Texas Medicaid Settlement, Attorney General Paxton SaysOctober 23 at 12:47 PM | finance.yahoo.comGilead To Buy PepStar's IBD Investigational Oral IL-23R Inhibitor Program For $1.275 Bln CashOctober 23 at 7:46 AM | rttnews.comGilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 3,000 Shares of Company StockOctober 17, 2026 | insidertrades.comInsider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Company StockOctober 3, 2026 | insidertrades.comSee More Headlines GILD Stock Analysis - Frequently Asked Questions How have GILD shares performed this year? Gilead Sciences' stock was trading at $122.74 at the beginning of 2026. Since then, GILD stock has increased by 27.1% and is now trading at $156.04. How were Gilead Sciences' earnings last quarter? Gilead Sciences, Inc. (NASDAQ:GILD) posted its earnings results on Monday, August, 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. The company's quarterly revenue was up 10.6% compared to the same quarter last year. Read the conference call transcript. Does Gilead Sciences have any subsidiaries? Gilead Sciences subsidiaries include MYR, Immunomedics, Forty Seven, Cell Design Labs, Kite Pharma, Nimbus Apollo, Epitherapeutics, and more. Who are Gilead Sciences' major shareholders? Gilead Sciences' top institutional investors include Robeco Institutional Asset Management B.V. (0.28%), Assenagon Asset Management S.A. (0.13%), Confluence Investment Management LLC (0.06%) and Crossmark Global Holdings Inc. (0.03%). Insiders that own company stock include Daniel Patrick O'day, Andrew D Dickinson, Johanna Mercier, Merdad Parsey, Deborah H Telman, Anthony Welters, Jeffrey Bluestone and Kelly A Kramer. View institutional ownership trends. How do I buy shares of Gilead Sciences? Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gilead Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gilead Sciences investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Alibaba Group (BABA) and Intel (INTC). Company Calendar Last Earnings8/03/2026Record date for 9/29 Dividend9/15/2026Ex-Dividend for 9/29 Dividend9/15/2026Dividend Payable9/29/2026Today10/24/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 GILD's financial health is in the Green zone, according to TradeSmith. GILD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GILD CIK882095 Webwww.gilead.com Phone(650) 574-3000Fax650-578-9264Employees17,000Year Founded1987Price Target and Rating Average Price Target for Gilead Sciences$159.81 High Price Target$185.00 Low Price Target$126.00 Potential Upside/Downside+2.4%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage29 Analysts Profitability EPS (Trailing Twelve Months)($2.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$8.51 billion Net Margins-10.64% Pretax Margin-6.42% Return on Equity-2.11% Return on Assets-0.75% Debt Debt-to-Equity Ratio2.03 Current Ratio1.27 Quick Ratio1.09 Sales & Book Value Annual Sales$29.44 billion Price / Sales6.57 Cash Flow$10.47 per share Price / Cash Flow14.90 Book Value$18.23 per share Price / Book8.56Miscellaneous Outstanding Shares1,239,950,000Free Float1,236,235,000Market Cap$193.48 billion OptionableOptionable Beta0.31 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:GILD) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredYou haven't downloaded this yetBill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork,...Behind the Markets | SponsoredTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredAsk a 20 Year Trading Pro Your Stock Questions Live for 5Ross Givens, a market analyst with over 20 years on Wall Street, goes live every Monday at 9 AM ET to break do...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
